Protara Therapeutics, Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Protara Therapeutics, Inc. payments for repurchase of common stock for the quarter ending 2024-03-31 was $76.00K, a 18.75% increase year-over-year.
- Protara Therapeutics, Inc. payments for repurchase of common stock for the quarter ending 2023-12-31 was $0.00.
- Protara Therapeutics, Inc. payments for repurchase of common stock for the quarter ending 2023-09-30 was $27.00K, a 50.00% increase year-over-year.
- Protara Therapeutics, Inc. payments for repurchase of common stock for the quarter ending 2023-06-30 was $0.00.
- Protara Therapeutics, Inc. payments for repurchase of common stock for fiscal 2023 was $91.00K, a 1.11% increase from fiscal 2022.
- Protara Therapeutics, Inc. payments for repurchase of common stock for fiscal 2022 was $90.00K, a 60.53% decline from fiscal 2021.
- Protara Therapeutics, Inc. payments for repurchase of common stock for fiscal 2021 was $228.00K.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2024-03-31 | $76.00K 10-Q · filed 2024-05-02 | $103.00K derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $91.00K 10-K · filed 2024-03-13 |
| 2023-09-30 | $27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $91.00K derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $82.00K derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-03-31 | $64.00K 10-Q · filed 2024-05-02 | $82.00K derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $90.00K 10-K · filed 2024-03-13 |
| 2022-09-30 | $18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $90.00K derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $72.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $72.00K 10-Q · filed 2023-05-04 | $72.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $228.00K 10-K · filed 2023-03-08 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | |
| 2021-03-31 | $228.00K 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |